TY - JOUR
T1 - Organotrifluoroborate Sugar Conjugates for a Guided Boron Neutron Capture Therapy
T2 - From Synthesis to Positron Emission Tomography
AU - Confalonieri, Laura
AU - Imperio, Daniela
AU - Erhard, Alvaro
AU - Fallarini, Silvia
AU - Compostella, Federica
AU - Del Grosso, Erika
AU - Balcerzyk, Marcin
AU - Panza, Luigi
N1 - Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.
PY - 2022/12/27
Y1 - 2022/12/27
N2 - Sugars are a versatile tool for targeting malignant cells and have been extensively used for drug delivery and imaging techniques. Their prototype, fluorodeoxyglucose ([18F]FDG), is currently used for positron emission tomography. Boron neutron capture therapy (BNCT) is a cancer treatment that relies on irradiation with thermal neutrons of cancer cells previously loaded with [10B]-containing compounds. The recent introduction of accelerators as a neutron source for clinical use prompts the planning of delivery compounds enriched with boron able to be traced in real time. This work describes the first synthesis of a new class of sugar derivatives conjugated to a trifluoroborate moiety as potential theranostic agents. Stability and cytotoxicity studies are reported for all compounds, together with [18F] radiolabeling optimization and in vivo preliminary positron emission tomography (PET) experiments on a selected compound.
AB - Sugars are a versatile tool for targeting malignant cells and have been extensively used for drug delivery and imaging techniques. Their prototype, fluorodeoxyglucose ([18F]FDG), is currently used for positron emission tomography. Boron neutron capture therapy (BNCT) is a cancer treatment that relies on irradiation with thermal neutrons of cancer cells previously loaded with [10B]-containing compounds. The recent introduction of accelerators as a neutron source for clinical use prompts the planning of delivery compounds enriched with boron able to be traced in real time. This work describes the first synthesis of a new class of sugar derivatives conjugated to a trifluoroborate moiety as potential theranostic agents. Stability and cytotoxicity studies are reported for all compounds, together with [18F] radiolabeling optimization and in vivo preliminary positron emission tomography (PET) experiments on a selected compound.
UR - http://www.scopus.com/inward/record.url?scp=85143967197&partnerID=8YFLogxK
U2 - 10.1021/acsomega.2c06551
DO - 10.1021/acsomega.2c06551
M3 - Article
SN - 2470-1343
VL - 7
SP - 48340
EP - 48348
JO - ACS Omega
JF - ACS Omega
IS - 51
ER -